SOCOM broad agency announcement for research entitled, development of lyophilized cryoprecipitate for far forward military operations.
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH20C0099
- Awardee
-
Vascular Solutions LLC UEI CMZHMVNAALR1
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $1,718,657
Award facts
- Opportunity
-
- BROAD AGENCY ANNOUNCEMENT (BAA) for Extramural Biomedical Research and Development Special Notice · W81XWH18SSOC1 · Posted Aug 1, 2018
- Development of Lyophilized Cryoprecipitate for Far Forward Military Operations Award Notice · Posted Sep 21, 2020
- Contract value 76% obligated
-
- $2,178,724.00 Current, with exercised options
- $2,246,981.00 Potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Negotiated Proposal / Quote
- Pricing
- Fixed Price Level of Effort
- Place of performance
- Maple Grove, MN 55369, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Funding Only Action | -$460,067 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Funding Only Action | $968,816 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $628,097 | |
| Supplemental Agreement for work within scope | $0 | |
| Funding Only Action | $273,256 | |
| Original award | $308,556 |
About this award
Vascular Solutions LLC, a division of Teleflex Medical, was awarded a $2.25 million fixed-price level of effort contract by the Defense Health Agency on September 28, 2020, to develop lyophilized cryoprecipitate for far-forward military operations. The contract, which will be performed in Maple Grove, Minnesota, is scheduled for completion by December 31, 2024. This award was issued under the Special Operations Command (SOCOM) Broad Agency Announcement, which solicits extramural research and development proposals to advance knowledge in areas benefiting military and civilian medical practice under the authority of 10 U.S.C. § 2358. The original solicitation, posted on August 1, 2018, with a due date of July 31, 2023, did not utilize a set-aside designation.
The project focuses on creating a shelf-stable, lyophilized (freeze-dried) formulation of cryoprecipitate, a blood product containing fibrinogen and other clotting factors critical for trauma management. This innovation addresses a significant logistical challenge in military medicine by enabling the storage and transport of this hemostatic agent to remote or austere operational environments where traditional refrigerated cryoprecipitate cannot be practically maintained. The research falls within the Defense Health Agency's mission to support medical innovations that enhance battlefield medicine while potentially offering benefits to civilian emergency and trauma care systems.
Quick answers
Who was awarded contract W81XWH20C0099?
W81XWH20C0099 was awarded to Vascular Solutions LLC by Defense Health Agency (Department of Defense) on September 28, 2020.
How much is contract W81XWH20C0099 worth?
The government has obligated $1,718,657 on W81XWH20C0099. Its current value, with exercised options, is $2,178,724. Its potential value, with all options, is $2,246,981.
Was contract W81XWH20C0099 competed?
The extent of competition for W81XWH20C0099 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award